Genelux: Olvi-Vec estimated billion+ US market; interim data in recurrent NSCLC expected mid-2024

GENELUX Corp

Olvi-Vec estimated to represent more than $1 billion annual US market opportunity.
Interim data from systemic Olvi-Vec trials in recurrent NSCLC expected as early as mid-2024.
Corporate presentation outlines pipeline and commercial potential for lead candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.